Amandeep Singh*, Kirandeep Kaur, Uttam Kumar Mandal and Raj Kumar Narang Pages 225 - 247 ( 23 )
Inflammatory Bowel Disease (IBD) is a disorder of the gastrointestinal tract, which is characterized by Crohn’s disease and Ulcerative colitis. Ulcerative colitis (UC) is a chronic idiopathic relapsing colon disease distinguishes by the interference of epithelial wall and colonic site tenderness. For the treatment of ulcerative colitis, various side effects have been reported, due to the non-specific delivery of the targeted drug of the conventional system. This review will explain the reader about various considerations for the preparation of orally administered NPs drug delivery systems for the treatment of ulcerative colitis. Moreover, principles and novel strategies for colon targeting based on the physiology of colon so that the tract of gastro intestine can be used as the identification marker for a target site for drugs. Besides this, the role of phytomedicines in controlling and managing the ulcerative colitis has been discussed. Additionally, the major problem for the smart delivery of NPs in clinical applications with their difficulties in Intellectual Property Rights (IPR) was also discussed. Finally, this review provides various potential approaches to NPs for the treatment of UC.
Colon targeted drug delivery, identification markers, nanoparticles, ulcerative colitis, Inflammatory Bowel Disease (IBD), Crohn’s disease.
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Maharaja Ranjit Singh Punjab Technical University, Department of Pharmaceutics, Bathinda, Department of Pharmaceutics, ISF College of Pharmacy, Moga